"Teva stifled would-be generic competitors to QVAR because the drug laws do not allow for generic substitution of a given ...
The cost of drugs in the U.S. continues to skyrocket. The average drug price increase from 2022 to 2023 was 15%, according to the United States Department of Health and Human Services. Some federal ...
The average drug price increase from 2022 to 2023 was 15%, according to the United States Department of Health and Human Services. The Federal Trade Commission says drug makers are gaming the system ...
The cost of drugs in the U.S. continues to skyrocket. The average drug price increase from 2022 to 2023 was 15%, according to the United States Department of Health and Human Services. Some federal ...
Although drug manufacturers have steadily increased the number of patents on their products over the past few decades, they have largely evaded government pushback—until now. The Federal Trade ...
Related: FTC targets 300 Big Pharma 'junk patents,' sends warning letters to top drugmakers The committee already has passed several bipartisan bills targeting "pay-for-delay" agreements, in which ...
CareDx Reiterates Position that it Does Not Infringe Natera’s ‘544 Patent Injunction Motion has No Impact on CareDx’s Business or Patient and Clinician Access to AlloSure or AlloMap BRISBANE ...